Abstract:  The treatment of advanced oral and maxillofacial-head and neck squamous cell carcinoma(SCCHN) is still a challenge in the section of oncology in oral and maxillofacial surgery. Although the traditional treatments like radical surgical operation combined with radiotherapy or chemotherapy has progressed a lot recently, the prognosis of the advanced SCCHN is still poor. However, the progress of target drugs brings hope for it. Two primary strategies have emerged that account for most of the success of current targeted therapies: one is epidermal growth factor receptor (EGFR), and the other is vascular endothelial growth factor (VEGF) receptor. The typical drugs to block EGFR are cetuximab and nimotuzumab, both of them have demonstrated survival benefits across whatever monotherapy, or multitherapy with radiotherapy or chemotherapy. The typical drug to block VEGF is bevacizumab, which is now proceeding through  Phase III clinical trial.  The targeted therapy is a new choice for the advanced SCCHN.

Key words: squamous cell carcinoma of oral and maxillofacial-head and neck, targeted therapy, epidermal growth factor receptor（EGFR）, vascular endothelial growth factor receptor （VEGF）, cetuximab, nimotuzumab, bevacizumab

摘要： 晚期口腔颌面-头颈部鳞癌的治疗仍然是个巨大的挑战。尽管传统的手术、放疗及化疗已取得了很大的进展，但晚期口腔颌面?鄄头颈部鳞癌的预后仍然较差，分子靶向药物为此带来了新的希望。目前针对口腔颌面?鄄头颈部鳞癌的靶向治疗的靶点主要有表皮生长因子受体及血管内皮生长因子受体。前者的代表药物有西妥昔单抗及尼妥珠单抗，他们无论是单药治疗，还是与放化疗结合治疗，均表现出了良好的前景；后者的代表药物主要是贝伐单抗，也已经进行到临床III期实验。靶向治疗为晚期口腔颌面?鄄头颈部鳞癌的治疗提供了新的机遇。

关键词: 口腔颌面-头颈部鳞癌, 靶向治疗, 表皮生长因子受体, 血管内皮生长因子受体, 西妥昔单抗, 尼妥珠单抗, 贝伐单抗

CLC Number: 

• R739.81